Launches new program to supply blood products from COVID-19 convalescent donors LOWELL, MA and MEMPHIS, TN – April 29, 2020 – Key Biologics and Astarte Biologics, together the leading provider of research- and clinical-grade human immune cells, blood products, and related services to the biopharmaceutical industry, today announced the launch of an IRB-approved initiative to…
Recovered patients carrying SARS-CoV-2 antibodies are being collected under Key Biologics newest IRB-Approved protocol to help drive therapeutic agent & vaccine development. Responding to the FDA’s call-to-action for convalesced plasma & other blood products collection, and to meet mounting requests from institutional & biopharmaceutical researchers in need of premium cells, Key Bio’s COVID-19 protocol is active in…
The Catalogue of Somatic Mutations in Cancer (COSMIC) is the world’s largest and most comprehensive resource for exploring the impact of somatic mutations in human cancer. Why We Love COSMIC 1. The website is an easy, one-stop reference for all information about specific genes and mutations. 2. The cancer browser shows mutations that are…
Key Biologics (A Cellero Company) is open and maintaining normal operations. To ensure that we can maintain normal operations as the spread of COVID-19 continues, we have activated our business continuity plans. Our management teams are focused on overseeing our response to the evolving situation. COVID-19 has not impacted Key Biologics’ ability to deliver any…
Assessing an individual’s eligibility to safely donate blood products has always been and remains our highest priority. To accomplish this, we use a several stepped process, learn more about our process below. Key Biologics (A Cellero Company) has transitioned over the past two plus decades from a department within an FDA-registered community blood center providing…
Our scientists bring a wealth of immunology research expertise from diverse backgrounds. With extensive experience in a variety of biologics disciplines, our team is an ideal resource for a wide range of outsource research services. From multiplex assays to flow cytometric analyses, we help you get on with discovery. In this Researcher Spotlight, we introduce…
MAGE-A10 is highly expressed in triple-negative breast cancers (Estrogen Receptor / Progesterone Receptor / HER-2-negative), an important focus for many cancer researchers. We have developed a new T cell line specific for the MAGE-A10254-263 peptide (GLYDGMEHL) and restricted by HLA-A*0201. These MAGE-A10 T cells could be the perfect complement to your cancer immunotherapy research. View…
A curious researcher recently asked us to suggest suitable antigens that could stimulate IFNγ producing CD8+ T cells. The short answer: Virus proteins. But as with anything in immunology and virology, there is a longer, more complicated explanation as well. Protein Antigens vs. Peptide Antigens CD8+ T cells normally recognize antigens that are produced…
What is the HER2 Antigen? HER2 is a tumor-related antigen also known as ERBB2 or NEU. The HER2 gene encodes a human epidermal growth factor receptor (EGFR) that is overexpressed by several tumor types, most notably in breast and ovarian cancers. Many women (and men) are interested to know their HER2 status. HER2 gene amplification…
For decades, medical professionals and researchers have relied on and even preferred stem cells derived from bone marrow for transplantation and research purposes. When bone marrow transplantation began in 1956, this was the only way to harness the body’s most versatile cells. In the nearly 65 years since the first successful bone marrow transplant, there…